You Zhang, Min Cao, Yanfei Wu, Sara Malih, Dong Xu, Erpeng Yang, Muhsin H Younis, Wilson Lin, Haitao Zhao, Cheng Wang, Qiufang Liu, Jonathan W Engle, Mohammad J Rasaee, Yihui Guan, Gang Huang, Jianjun Liu, Weibo Cai, Fang Xie, Weijun Wei
BACKGROUND: The programmed cell death protein-1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis critically facilitates cancer cells' immune evasion. Antibody therapeutics targeting the PD-1/PD-L1 axis have shown remarkable efficacy in various tumors. Immuno-positron emission tomography (ImmunoPET) imaging of PD-L1 expression may help reshape solid tumors' immunotherapy landscape. METHODS: By immunizing an alpaca with recombinant human PD-L1, three clones of the <u>v</u>ariable domain of the <u>h</u>eavy chain of <u>h</u>eavy-chain only antibody (VHH) were screened, and RW102 with high binding affinity was selected for further studies...
April 5, 2024: Journal for Immunotherapy of Cancer